Sandoz to become standalone company
A spin-off from parent company Novartis aims to set Sandoz up as the premier European generics company.
List view / Grid view
A spin-off from parent company Novartis aims to set Sandoz up as the premier European generics company.
As biopharmaceuticals become an increasingly important part of the drug development pipeline and market, EPR discusses key trends in the outsourcing of their manufacturing.
Growth in the global pharmaceutical contract manufacturing market will be driven by rising consumption of medicines and increasing commercialisation of generic and innovative therapies, among other factors.
Under a collaboration agreement Merck will pay Orna $150 million to support the progress of multiple oRNA vaccine and therapeutic programmes.
The Frost & Sullivan Institute to present CDMO Samsung Biologics with a Global Enlightened Growth Leadership Award for its commitment to sustainable growth and protecting and prolonging human lives.
The acquisition will boost Gilead’s capabilities in exploring checkpoint agonist antibodies for treating patients with autoimmune disease, complementing its inflammation research and development strategy.
Subin Baral, Global Deals Leader, Life Sciences, Ernst & Young LLP, offers his predictions for M&A activity within industry as we head into the later stages of 2022.
In this whitepaper, authors have shared their experience on AI-driven technology adoption in pharmacovigilance.
Innovations in the use of viral vectors as a gene delivery vehicle are a key factor in the growth of the gene and cell therapy field.
Why do pharmaceutical manufacturers still believe older methods are reliable for quality testing when there’s superior technology available on the market?
Under the agreement, Recipharm will help advance two inhaled medicines intended for asthma and chronic obstructive pulmonary disease (COPD).
This whitepaper shares how analytical solutions from METTLER TOLEDO can be used to characterise COVID-19 vaccines.
Ex-MHRA inspector and NSF expert, Rachel Carmichael, takes a high-level look at why Data Integrity matters in this online introduction training.
The investigational mRNA-1215 vaccine developed to prevent Nipah virus – a bat-borne disease of pandemic potential, will be evaluated for safety, tolerability and immunogenicity.
Dr Eric Hughes will join Teva as Executive Vice President, Global R&D and Chief Medical Officer in August, assuming the role from Dr Hafrun Fridriksdottir, who has been with Teva for 25 years.